Background. Homoarginine is a novel biomarker for cardiovascular diseases. In the present large cohort study, we evaluate how homoarginine is linked to kidney function and examine the potential interaction of homoarginine and kidney function as predictors of cardiovascular outcomes. Methods. Serum homoarginine (mean: 2.41 ± 1.05 µmol/L), cystatin C and creatinine-based estimated GFR (eGFR, mean: 86.2 ± 23.0 mL/min per 1.73 m 2 ) were measured in 3037 patients (mean age: 62.8 ± 10.6 years; 31.5% women) who were referred to coronary angiography. Results. Homoarginine was positively associated with eGFR (age-and gender-adjusted partial correlation coefficient: 0.20, P < 0.001); using multiple regression analysis, eGFR emerged as an independent predictor of serum homoarginine (β = 0.10, SE 0.01, P < 0.001). Overall cardiovascular mortality was 18.5% (563 cardiovascular deaths) after 9.9 years. Multivariate Cox proportional hazard analysis revealed that compared with participants in the highest gender-specific homoarginine tertile, those in the lowest tertile were at increased risk of cardiovascular death [multivariate-adjusted
A B S T R AC T
Background. Homoarginine is a novel biomarker for cardiovascular diseases. In the present large cohort study, we evaluate how homoarginine is linked to kidney function and examine the potential interaction of homoarginine and kidney function as predictors of cardiovascular outcomes. Methods. Serum homoarginine (mean: 2.41 ± 1.05 µmol/L), cystatin C and creatinine-based estimated GFR (eGFR, mean: 86.2 ± 23.0 mL/min per 1.73 m 2 ) were measured in 3037 patients (mean age: 62.8 ± 10.6 years; 31.5% women) who were referred to coronary angiography. Results. Homoarginine was positively associated with eGFR (age-and gender-adjusted partial correlation coefficient: 0.20, P < 0.001); using multiple regression analysis, eGFR emerged as an independent predictor of serum homoarginine (β = 0.10, SE 0.01, P < 0.001). Overall cardiovascular mortality was 18.5% (563 cardiovascular deaths) after 9.9 years. Multivariate Cox proportional hazard analysis revealed that compared with participants in the highest gender-specific homoarginine tertile, those in the lowest tertile were at increased risk of cardiovascular death [multivariate-adjusted HR 1.47; 95% confidence interval (95% CI) 1.15-1.87, P = 0.002]. After adjustment for confounders, both homoarginine and eGFR were associated independently with cardiovascular mortality, with a strong synergistic interaction (P for interaction 0.005). After stratifying the cohort into persons with eGFRs <60 and ≥60 mL/min per 1.73 m 2 , there was a stronger association between homoarginine and cardiovascular mortality in patients within eGFR below 60 (mean: 46.5 ± 12.0 mL/min per 1.73 m 2 ; HR per log SD increment of homoarginine 0.78; 95% CI 0.65-0.95, P = 0.013) compared to those with eGFR values ≥60 mL/min per 1.73 m 2 . Subgroup analysis revealed that homoarginine is exclusively associated with death due to heart failure in subjects with eGFR values <60 mL/min per 1.73 m 2 (HR per log SD 0.56; 95% CI 0.37-0.85; P = 0.006). Conclusions. Low homoarginine is strongly related to decreased kidney function, adverse cardiovascular events and death due to heart failure. The relationship between low homoarginine and adverse cardiovascular outcomes is most obvious when kidney function is impaired.
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Homoarginine is a cationic amino acid derivative found at high amounts in seeds of grass peas (Lathyrus sativus and Lathyrus cicera) almost 50 years ago [1, 2] . Trace amounts of circulating homoarginine have also been found in avian and mammalian species [3] . In the recent past, homoarginine increasingly attracted scientific attention because of its potential interactions with insulin secretion, platelet aggregation, blood pressure regulation and endothelial function [4] [5] [6] [7] . März et al. demonstrated a strong association between low homoarginine levels and higher mortality risk in coronary heart disease and haemodialysis patients, respectively [8] . In particular, homoarginine deficiency is closely related to myocardial dysfunction and stroke [9, 10] .
Although enzymes involved in homoarginine metabolism have been detected in the human kidney, the exact pathways of homoarginine synthesis and their associations with kidney function in humans have so far remained elusive. Ryan and Wells [11] have suggested that homoarginine is synthesized in the kidney by transamidation of lysine. Subsequent studies in animals revealed an inconsistent picture of the role of the kidney in determining serum, plasma and urinary levels of homoarginine [12] [13] [14] .
Considering that individuals with chronic kidney disease (CKD) are more likely to die from cardiovascular disease (CVD) than to progress to end-stage kidney failure, the search for novel CVD risk factors in this population may yield novel therapeutic strategies [15] . Drechsler et al. [16] found a strong association between low homoarginine levels and both risk of sudden cardiac death (SCD) and death due to heart failure, respectively, in haemodialysis patients. Zoccali et al. [17] found that plasma homoarginine is a strong inverse predictor of progression to dialysis and incident mortality in predialysis CKD patients.
The relationship between circulating homoarginine and CVD mortality in patients with normal and mildly decreased kidney function under consideration of various potential confounders is, however, unknown. This prompted us to evaluate the association between serum homoarginine concentrations and risk of fatal cardiovascular events depending on kidney function in a large cohort of patients referred to coronary angiography, who had a long-term follow-up of almost 10 years.
M AT E R I A L S A N D M E T H O D S

Study design and participants
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study included consecutive patients of Caucasian origin hospitalized for coronary angiography in a tertiary care centre in south-west Germany (Heart Center Ludwigshafen). The LURIC study was designed as a prospective cohort study in order to investigate environmental and genetic risk factors for CVDs [18] . Between June 1997 and May 2001, 3316 (3305 with homoarginine measurement at baseline) study participants were enrolled. Inclusion criteria were the availability of a coronary angiogram, clinical stability with the exception of acute coronary syndrome (ACS), and Caucasian origin, in order to limit genetic heterogeneity. Indications for coronary angiography were chest pain or non-invasive tests raising suspicion of myocardial ischaemia. Exclusion criteria were any acute illness other than ACS and any chronic disease where non-cardiac disease pre-dominated a history of malignancy within the past 5 years. These exclusion criteria were pre-specified in order to minimize the impact of concomitant non-CVD on intermediate biochemical phenotypes or on clinical prognosis (limitation of clinical heterogeneity). Patients with either intravenous iron supplementation and/or active vitamin D treatment were not enrolled. Information on vital status was obtained during continuous follow-up. Two experienced clinicians, who were blinded to patient characteristics, classified the causes of fatal events by independently examining death certificates and medical records.
Informed written consent was obtained from all study participants and approval for the study was obtained from the ethics committee at the 'Ärztekammer Rheinland-Pfalz' (Mainz, Germany). The LURIC study complies with the Declaration of Helsinki.
Detailed descriptions of the baseline examination in LURIC have been published [18] . In brief, angiographic coronary artery disease (CAD) was diagnosed in patients with at least one stenosis ≥50% of at least 1 of 15 coronary segments, using the maximal luminal narrowing estimated by visual analysis. Previous acute myocardial infarction (MI) was recorded based on a documented history of electrocardiographic ST-and non-ST-elevation and/or elevation of cardiac biomarkers. ACS was defined as presentation with unstable angina pectoris, non-ST-elevation MI (troponin T ≥ 0.1 mg/L) or STelevation MI (troponin T ≥ 0.1 mg/L) within 7 days after the onset of symptoms. LV ejection fraction (LVEF) was calculated from the right anterior oblique view during catheterization in a subgroup of participants (n = 1174). Brachial artery pressure values were measured with an automated oscillometric device (Omron MX4, Omron Health Care GmbH, Hamburg, Germany) after the patient had rested in the supine position for 10 min. At least three consecutive systolic blood pressure (BP) and diastolic BP measurements were taken with a minimum interval of 30 s. Diabetes was classified according to the American Diabetes Association including the new criterion of glycosylated haemoglobin A1c (HbA1c) ≥6.5% [19] . All patients were on a normal Western (sodium) diet.
Follow-up
Information on vital status was obtained from local person registries. Hospital records and death certificates were reviewed to classify the causes of death. Cardiovascular deaths included SCD, fatal MI, deaths due to heart failure, deaths after intervention to treat CAD, stroke and other deaths due to heart disease. SCD was defined as an unexpected death either within 1 h of symptom onset or within 24 h of having been observed alive and symptom free [20, 21] . Persons whose sudden death was most likely attributable to a non-cardiac disease and patients who suffered from any predominant non-cardiac and terminal disease (e.g. cancer) so that their death was not unexpected were not classified as having died due to SCD. Three experienced clinicians who were blinded to homoarginine values and baseline characteristics of the study probands independently classified the causes of death.
Laboratory analysis
Venous blood sampling was performed in supine position in the morning (between 8.00 and 10.00 a.m.) before coronary angiography, and routine laboratory parameters were immediately measured on a daily basis as previously published. Otherwise, remaining blood samples were snap-frozen for further determinations and stored at −80°C until analysis.
Homoarginine was uniformly measured using reverse phase high-performance liquid chromatography method. Intra-day coefficients of variation (CVs) at different concentrations (mean levels) were 4.7% (1.21 µmol/L) and 2.2% (3.53 µmol/L), and between-day CVs were 7.9% (1.25 µmol/L) and 6.8% (3.66 µmol/ L), respectively. Arginine and lysine were measured in a subgroup of patients (n = 2010) by ion exchange chromatography followed by post-column continuous reaction with nihydrin [22] . Creatinine was determined by both a liquid chromatography with tandem mass spectrometry (lc-creatinine) and by Jaffe (twin) method. Cystatin C was measured in addition using a nephelometric assay (N LATEX Cystatin C, Behring nephelometer II, Dade Behring, Marburg, Germany). Estimated (e)GFR (mL/min per 1.73 m 2 ) was calculated from cystatin C (eGFR cystC ) according to the equation published by Hoek et al. [23] and from a combination of cystatin C and creatinine (eGFR crea/cystC ) according to the formula of Stevens et al. [24] . High-sensitivity CRP (hsCRP) was measured with immuno-nephelometry (Dade Behring). N-terminal pro-B-type natriuretic peptide-1 (NT-pBNP, ng/mL) was determined by electro-chemi-luminescence on an Elecsys 2010 (Roche Diagnostics). Glycated haemoglobin (HbA1c) was measured with an immunoassay (haemoglobin A1c UNIMATE 5; Roche Diagnostics, Mannheim, Germany). Haemoglobin was determined via an automated analyser (Technicon H-1, Technicon, Bad Vilbel, Germany). Lipoproteins were separated with a combined ultracentrifugation-precipitation method (β-quantification). Serum alanine transaminase (ALT) was assessed with an enzymatic assay (Hitachi 717; Roche Diagnostics). Serum albumin was measured with a photometric colour test (bromocresol green method; ALBUMIN liquicolor; Hitachi 717; Biochemica & Diagnostica; Wiesbaden, Germany). Asymmetrical dimethylarginine (ADMA) was measured in frozen serum (−80°C) with a reversed-phase HPLC method.
Statistical methods
Patients were stratified into gender-specific tertiles based on the distribution of serum homoarginine at baseline. Normally distributed continuous variables are reported as means (± SD), variables with skewed distribution as medians and interquartile ranges and categorical variables as percentages. For parametric procedures, all skewed continuous variables were logarithmically transformed.
Baseline characteristics were compared across homoarginine tertiles using the χ 2 trend test for categorical variables and analysis of variance for continuous variables. Cystatin C, creatinine, lc-creatinine, HbA1c, Total/HDL cholesterol ratio, NT-pBNP, hsCRP and ALT (which showed a skewed distribution) were compared between homoarginine tertiles using the Kruskal-Wallis test. Age-and gender-adjusted partial correlation analysis was calculated to evaluate associations between homoarginine and: (i) kidney function determined by eGFR crea/cystC and cystatin C; and (ii) homoarginine metabolism-related parameters (arginine, lysine, ALT, hsCRP and LVEF).
Evaluation of homoarginine across gender-specific eGFR crea/cystC deciles was performed by one-way analysis of co-variance (ANCOVA) followed by Bonferroni's post hoc test and adjusted for age.
Multiple variable regression analyses (with backward elimination), with log-transformed homoarginine ( per doubling) as the dependent variable, were used to estimate associations between homoarginine and eGFR crea/cystC , proposed factors affecting homoarginine metabolism and factors related to homoarginine in univariate analyses [age, gender, arginine, lysine, body mass index (BMI), serum albumin, haemoglobin, serum ALT, HDL/LDL cholesterol, smoking status, treated systolic BP, hsCRP, NT-pBNP, HbA1c, acute MI, ADMA, use of ACE-inhibitors, use of β-blockers and use of diuretics] as independent variables.
The association of homoarginine with CVD mortality was analysed with multivariate Cox regression models and the final step derived from backward procedures is presented. Beside presenting a crude model (model 1), variables considered for a multivariate model 2 included age, gender, BMI, smoking status, HDL cholesterol, LDL cholesterol, haemoglobin, combined eGFR crea/cystC , acute MI, NT-pBNP, diabetes mellitus, systolic BP, serum albumin and hsCRP. A model 3 was additionally adjusted for the use of ACE-inhibitors, angiotensin II type 1 receptor blockers, calcium-channel blockers, β-blockers, diuretics and statins. Finally, one additional model (on top of model 3) was calculated considering ADMA as potential confounder. For homoarginine as a continuous variable, the hazard ratio (HR) [with 95% confidence interval (CI)] was calculated per log standard deviation (SD). Interaction terms comprising eGFR crea/cystC and homoarginine (both as continuous variables) were introduced into the fully adjusted Cox models. To evaluate the association between homoarginine and the risk of fatal CVD events as a function of eGFR crea/cystC , we further assessed the association of homoarginine as continuous variable (HR for increment per log SD), with CVD mortality in fully adjusted Cox proportional hazard analyses after stratifying the cohort according to genderspecific eGFR crea/cystC values of <60 and ≥60 mL/min per 1.73 m 2 . A P-value of <0.05 was considered statistically significant.
Data were analysed using SPSS 17.0 statistical package (SPSS, Inc., Chicago, IL, USA) and STATA Statistical Software, version 10.0 (Stata Corp, College Station, TX, USA).
R E S U LT S
In the entire cohort (n = 3037) of ACS (31.5%) and non-ACS patients with combined homoarginine and cystatin
O R I G I N A L A R T I C L E
H o m o a r g i n i n e , k i d n e y , m o r t a l i t y C measurements at baseline, the mean homoarginine concentration was 2.41 ± 1.05 µmol/L and the mean eGFR crea/cystC was 86.2 ± 23.0 mL/min per 1.73 m 2 , respectively. The characteristics of the study population by gender-specific tertiles of homoarginine are shown in Table 1 .
Age-and gender-adjusted partial correlation analyses revealed a significant positive correlation between homoarginine and eGFR crea/cystC (r = 0.20, P < 0.001) and a strong inverse correlation between homoarginine and cystatin C (r = −0.27, P < 0.001). Strong positive associations were also found 
and ALT (r = 0.03, P = 0.245).
We further observed inverse correlations between hsCRP and homoarginine (r = −0.22), hsCRP and arginine (r = −0.18) and hsCRP and lysine (r = −0.08; P < 0.001 for all). These correlations were stronger in patients with eGFR crea/cystC values of <60 mL/min per 1.73 m 2 : homoarginine and hsCRP (r = −0.23), arginine and hsCRP (r = −0.22) and lysine and hsCRP (r = −0.26; P < 0.001 for all) compared with persons with eGFR crea/cystC ≥60 mL/min per 1.73 m 2 . In patients with LVEF determination at baseline (n = 1174), partial correlation analysis revealed a positive association between LVEF and homoarginine (r = 0.274; P < 0.001). After stratifying the cohort according to eGFR crea/cystC values of <60 (n = 142) and ≥60 mL/min per 1.73 m 2 (n = 1032), the correlation between homoarginine and LVEF was stronger in eGFRs <60 (r = 0.329; P < 0.001) compared with eGFRs ≥60 mL/min per 1.73 m 2 (r = 0.251; P < 0.001). In order to further illustrate the relationship of homoarginine and kidney function, both gender-specific eGFR cystC and eGFR crea/cystC deciles, respectively, were formed comprising between 286 and 327 persons in each decile. In age-adjusted ANCOVA homoarginine progressively increased (P < 0.001) in parallel to both gender-specific eGFR cystC and eGFR crea/cystC , respectively (Figure 1) .
In stepwise multiple linear regression (R 2 : 0.33) analysis arginine, NT-pBNP, lysine, BMI, haemoglobin and eGFR crea/cystC emerged as the strongest predictors for homoarginine (Table 2) .
Mortality rates
After a median follow-up of 9.9 years, a total of 563 participants (18.5%) with homoarginine and cystatin C measurements at baseline had died from cardiovascular causes. There were 237 SCDs, 98 fatal MI, 132 deaths due to congestive heart failure (NYHA classification > I), 23 deaths after intervention for coronary heart disease, 73 due to other complications of coronary heart disease.
Cox proportional hazard analyses were performed to evaluate the association between homoarginine [in gender-specific tertiles and as continuous variable (increment per log SD)] and CVD mortality. Results of the sequential modelling of homoarginine in subjects with fatal CVD events are given in Table 3 . In crude and multivariable models adjusting for other potential clinical predictors of CVD mortality, lower homoarginine independently contributed to the prediction of fatal CVD events. In unadjusted analysis, for each log SD (µmol/L) lower serum homoarginine, the risk of death from CV causes was higher by 22% [HR 0.78; 95% confidence interval (95% CI) 0.71-0.85, P < 0.001]. Again, after adjusting for established CVD risk factors the relationship between serum homoarginine and CVD mortality only marginally changed. Compared with patients with the highest homoarginine concentrations, the adjusted HRs for CVD death were 1.47 for patients in the first gender-specific tertile (95% CI 1.15-1.87; P = 0.002). After backward elimination eGFR crea/cystC , age, gender, acute MI, NT-pBNP, diabetes mellitus, use of β-blockers and use of diuretics remained in the final model in addition to homoarginine.
In fully adjusted Cox analysis, we found a significant interaction for CVD mortality between eGFR crea/cystC and homoarginine (Table 3) , respectively.
Cox proportional hazard analyses were repeated to evaluate the association between homoarginine (as a continuous variable; increment per log SD) and CVD mortality after stratifying the cohort according to eGFR crea/cystC <60 and ≥60 mL/min per 1.73 m 2 (Table 4 ). In patients with eGFR crea/cystC <60 mL/min per 1.73 m 2 (n = 366; 12.1%) stronger associations (HR 0.78;
Age-adjusted analysis of the variation of serum homoarginine values across gender-specific deciles of eGFR cystC and eGFR crea/cystC values, respectively. P < 0.001 for trend for the differences of homoargine across both deciles of eGFR.
O R I G I N A L A R T I C L E
H o m o a r g i n i n e , k i d n e y , m o r t a l i t y 95% CI 0.65-0.95, P = 0.013) between serum homoarginine concentrations and CVD mortality were found after full adjustment. Serum homoarginine, age, diabetes mellitus, eGFR crea/cystC , ARB use and systolic BP remained in the final step after backward elimination.
In subjects with eGFR crea/cystC ≥60 mL/min per 1.73 m 2 (n = 2671; 87.9%), a moderate relationship between serum homoarginine and risk of CVD death was found (HR 0.88; 95% CI 0.78-0.98, P = 0.024). In participants with eGFR crea/cystC ≥90 mL/min per 1.73 m 2 (n = 1321; 43.5%), the association between homoarginine and CVD mortality was even weaker (HR 0.89; 95% CI 0.75-1.05, P = 0.158).
In fully adjusted analyses for specific causes of CVD death each standard deviation increase in homoarginine ( per log SD) was associated with a 54% (HR 0.56; 95% CI 0.37-0.85; P = 0.006) lower risk for death due to HF. In addition, after backward elimination age, diabetes mellitus, eGFR crea/cystC , a Combined cystatin C-creatinine-based eGFR.
*The P-values for homoarginine per SD increment correspond to the global P-values for gender-specific homoarginine tertiles. **Global P-values of homoarginine tertiles within each model. Table 2 . Multivariate linear regression analysis to evaluate the relationship between homoarginine (per doubling of log-homoarginine) as independent variable and suggested factors affecting homoarginine levels as independent variables (overall R calcium-channel blocker use, BMI, haemoglobin, hsCRP and NT-pBNP remained in the final model.
After repeating the Cox proportional hazard analyses in persons with eGFR crea/cystC ≥60 mL/min per 1.73 m 2 no significant association between serum homoarginine and risk of heart failure death was found.
Additional adjustment for ADMA did not materially change the association between homoarginine and CVD death as well as heart failure death in both, the overall cohort and after stratification according to eGFR values, respectively.
No associations between homoarginine and death due to MI as well as SCD were seen in the overall cohort and in subgroups after stratification of probands according to eGFR < and ≥60 mL/min per 1.73 m 2 , respectively (data not shown). Finally, the percentage of cardiovascular deaths and deaths due to heart failure, respectively, according to eGFR crea/cystC subgroups and homoarginine tertiles are shown in Figure 2A and B. The highest percentage of CVD deaths and death due to HF were recorded in the subgroup with eGFR crea/cystC <60 mL/min per 1.73 m 2 and low circulating homoarginine.
D I S C U S S I O N
This study examined the association between kidney function, CVD mortality and homoarginine in a CAD population with either normal or mildly decreased kidney function. We observed a strong and independent association between homoarginine and glomerular filtration rates. We further demonstrated that low homoarginine is strongly linked to increased CVD mortality in patients with eGFR <60 mL/min per 1.73 m 2 , whereas this association was weakened in patients with eGFR >60 mL/min per 1.73 m 2 . It was specifically in the patient group with eGFR <60 mL/min per 1.73 m 2 that low homoarginine concentrations were strongly and independently associated with a higher risk of death due to heart failure.
Increasing evidence points to a pivotal role of the mitochondrial arginine:glycine amidinotransferase (AGAT; encoded by the GATM gene), which is regarded as a key enzyme in energy metabolism by catalysing the synthesis of guanidinoacetate, in homoarginine formation from its precursors arginine and lysine [2, 11, [25] [26] [27] . In a recently published genome-wide association study (GWAS) in two large cohorts, the GATM locus on chromosome 15 had the strongest association with circulating homoarginine [28] . Experimental studies support a strong relationship between AGAT expression, homoarginine and kidney function [13, 29] .
Furthermore, GWAS identified a strong association between an SNP at the GATM gene and both creatinine concentrationand creatinine-based eGFR [30, 31] . The authors speculated that this association might reflect that serum creatinine levels are determined in part by AGAT activity. Our findings indicate a relationship between kidney function and serum homoarginine, raising the possibility that serum homoarginine concentrations are reflecting renal AGAT activity. However, the cross-sectional relationship between serum homoarginine and kidney function was particularly strong in patients with eGFR <90 mL/min per 1.73 m 2 and flattens in subjects with eGFR >90 mL/min per ) and gender-specific serum homoarginine concentration tertiles (H T1-3) are considered concomitantly. Highest percentages of cardiovascular death (A) and death due to heart failure (B) during the study period were seen in subgroups with low eGFR and serum homoarginine concentration values. . Accordingly, we speculate that kidney function might play a minor role for AGAT activity and homoarginine generation in subjects with higher eGFR values.
Studies in humans demonstrating a relationship between circulating homoarginine and kidney function are sparse. A small study in humans has pointed to a strong relationship between homoarginine and glomerular filtration rate [29] . März et al. [8] observed significantly lower levels of homoarginine in haemodialysis compared with CAD patients without primary overt kidney disease. Drechsler et al. [32] documented a significant decline of homoarginine with decreasing kidney function in patients with mild-to-moderate kidney disease (mean eGFR 62 ± 41 mL/min/1.73 m 2 ). Zoccali et al. [17] reported a log-linear relationship between homoarginine and eGFR in predialysis CKD patients (mean eGFR 34 ± 18 mL/ min/1.73 m 2 ). We here extend these findings by showing that a positive association between homoarginine and eGFR exists in patients with either normal or mildly impaired kidney function (mean eGFR of 86.2 ± 23.0 mL/min per 1.73 m 2 ) independent of arginine, lysine and ADMA.
Our findings point at a strong dependence of homoarginine on the bioavailability of lysine and arginine. This is in line with previous studies in human, which demonstrated an increase of plasma and urine homoarginine after administration of lysine, and pointed to lysine as a potential rate-limiting factor for the generation of homoarginine in mammals [33, 34] . Further studies observed lower homoarginine concentrations as a result of decreased bioavailability of arginine for homoarginine synthesis via transamidation [35] .
Cullen et al. [36] demonstrated an organ-specific pattern of AGAT expression with highest levels in renal tissue from nonischaemic cardiomyopathy and stable end-stage heart failure patients. In the present analysis, a strong association between homoarginine and death due to heart failure was exclusively found in patients with eGFR <60 mL/min per 1.73 m 2 . Consistent with this finding, the positive correlation between homoarginine and LVEF was stronger in patients with decreased compared with those with normal kidney function. Impaired synthesis of homoarginine in patients with reduced kidney function might increase the cardiovascular and heart failure risk by several mechanisms. By inhibiting arginase, which increases the bioavailability of arginine, homoarginine might increase nitric oxide formation [8] . We observed a strong inverse relationship between homoarginine and hsCRP, which indicates an interplay between homoarginine, inflammation and NO metabolism. The formation of homoarginine by AGAT, which is also responsible for the production of creatine, might link homoarginine to energy metabolism [37, 38] . We speculate that patients with lower kidney function, and consequently lower AGAT activity, might be particularly prone to energy depletion in the myocardium.
Limitations
Our sample was primarily composed of elderly Caucasians of European ancestry referred to coronary angiography; thus, generalizations to other ethnicities and younger individuals cannot be made. In addition, urinary analyses of amino acids have not been performed. We further cannot exclude residual confounding e.g. by ongoing medication use. L-Arginine and L-lysine, which are suggested to play a pivotal role in homoarginine metabolism, have only been measured in a subgroup of patients and were not included within the multivariate Cox proportional hazard analyses, in order to achieve sufficient statistical power. We therefore cannot exclude the possibility of residual confounding by arginine and lysine. Data on urinary albumin:creatinine ratio were not available to further discriminate participants with eGFR between 60 to 90 mL/min per 1.73 m 2 from those with eGFR >90 mL/min per 1.73 m 2 and to evaluate the severity of the kidney damage. Finally, due to the observational design, we cannot draw conclusions with respect to causality. We are further aware that the interactions between homoarginine-eGFR and CVD mortality might be modified by both a differing range of the exposure within eGFR strata and differing numbers of events within the strata, respectively. However, the rather strong and independent cross-sectional association between kidney function and homoarginine underlines a feasible mechanistic interplay between both, and suggest a potential exposure-outcome relationship between homoarginine insufficiency and CVD mortality in patients with lower kidney function.
CO N C L U S I O N S
The current analysis adds significant evidence to our prior findings: (i) in multivariate-adjusted analysis, we revealed a strong and independent association between serum homoarginine and eGFR in patients at CVD risk with either normal or mildly decreased kidney function; (ii) we found strong interactions between homoarginine and kidney function as predictors of CVD mortality, indicating that kidney function modifies the relationship between homoarginine and risk of CVD death; and (iii) in eGFR stratified analyses, we demonstrated that the relationship between CVD mortality/death due to heart failure and homoarginine is particularly strong in patients with eGFR values <60 mL/min per 1.73 m 2 . Our findings suggest a potentially relevant pathway of incident CVD and death due to heart failure in patients with impaired kidney function. Because the underlying pathophysiological mechanisms are still elusive, future research should focus on the molecular mechanisms underlying the relationship between homoarginine-related CVD risk in moderately impaired kidney function and under consideration of further potential confounders such as L-arginine and L-lysine. mechanisms of cardiovascular diseases) with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive TMO. 
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